Blood thinning drugs before removing a clot in stroke patients improves mortality rates at 90 days, study finds – Medical Xpress


Forget Password?
Learn more
share this!
3
8
Share
Email
October 4, 2022
by
A new systematic review and meta-analysis by an international group of researchers has found giving a blood thinning drug (thrombolysis) before treatment to remove a clot from the brain—known as thrombectomy procedure—to stroke patients, improved mortality rates at 90 days, compared with just thrombectomy procedure alone.

googletag.cmd.push(function() { googletag.display(‘div-gpt-ad-1450190541376-1’); });

The research led by the University of Bristol and National University of Singapore, in collaboration with researchers in the U.K., Germany, Belgium, Sweden and Taiwan, is published in the Journal of NeuroInterventional Surgery.
Mechanical thrombectomy is an for patients with an caused by a clot () from basilar artery occlusion, which occurs when the basilar artery, the at the back portion of the brain, is blocked. Administering a bridging blood thinning drug before removing a clot is still recommended for most patients with large-vessel occlusion pending results of randomized controlled trials.
However, in patients with basilar artery occlusion who undergo , it is not clear whether or not prior treatment with a bridging blood thinning drug is beneficial. The research team wanted to compare the clinical outcomes of mechanical thrombectomy, with and without bridging intravenous thrombolysis, in acute basilar artery occlusion through a and meta-analysis of the current literature.
The review looked at 51 prior studies and three studies were eligible to be included in the study’s meta-analysis. The three studies compared bridging intravenous thrombolysis with direct mechanical thrombectomy in 1,096 patients with stroke due to basilar artery occlusion.
Of the total 1,096 patients, 749 were male (68.3%) and 347 were female (31.7%). 362 patients underwent mechanical thrombectomy with bridging intravenous thrombolysis, while 734 patients underwent direct mechanical thrombectomy.
The study found that in patients with due to basilar artery occlusion, compared with direct mechanical thrombectomy, bridging intravenous thrombolysis is associated with lower at 90 days without an increased risk of bleeding. Bridging intravenous thrombolysis is also associated with better functional outcomes particularly in patients with large atherosclerosis, which is the build-up of fatty material inside arteries. It’s a potentially serious condition that causes most heart attacks and strokes but often goes unnoticed.
Keng Siang Lee, a medical student and the study’s lead author from Bristol Medical School at the University of Bristol, said, “Our review has found in patients with acute ischemic stroke due to basilar artery occlusion, who present up to four and a half hours from the start of their stroke, bridging intravenous thrombolysis could improve their 90 day death rate.
“If our review is supported in future randomized controlled studies, it could become the standard treatment for stroke patients.”
The research team suggest future randomized controlled trials are needed to validate whether bridging intravenous thrombolysis does provide benefits over direct mechanical thrombectomy in stroke patients with basilar artery occlusion.


Explore further

More stroke patients could experience benefits from thrombectomy, studies show


More information: Keng Siang Lee et al, Bridging thrombolysis improves survival rates at 90 days compared with direct mechanical thrombectomy alone in acute ischemic stroke due to basilar artery occlusion: a systematic review and meta-analysis of 1096 patients, Journal of NeuroInterventional Surgery (2022). DOI: 10.1136/jnis-2022-019510

Citation: Blood thinning drugs before removing a clot in stroke patients improves mortality rates at 90 days, study finds (2022, October 4) retrieved 5 October 2022 from https://medicalxpress.com/news/2022-10-blood-thinning-drugs-clot-patients.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further
Facebook
Twitter
Email
Feedback to editors
Sep 30, 2022
0
Sep 29, 2022
0
Sep 27, 2022
0
Sep 26, 2022
0
Sep 23, 2022
1
1 hour ago
1 hour ago
10 hours ago
11 hours ago
11 hours ago
11 hours ago
13 hours ago
Jul 28, 2022
May 21, 2021
Aug 27, 2016
Feb 16, 2022
May 07, 2020
Dec 06, 2015
11 hours ago
13 hours ago
15 hours ago
Oct 04, 2022
19 hours ago
Oct 03, 2022
Use this form if you have come across a typo, inaccuracy or would like to send an edit request for the content on this page. For general inquiries, please use our contact form. For general feedback, use the public comments section below (please adhere to guidelines).
Please select the most appropriate category to facilitate processing of your request
Thank you for taking time to provide your feedback to the editors.
Your feedback is important to us. However, we do not guarantee individual replies due to the high volume of messages.
Your email address is used only to let the recipient know who sent the email. Neither your address nor the recipient’s address will be used for any other purpose. The information you enter will appear in your e-mail message and is not retained by Medical Xpress in any form.

Get weekly and/or daily updates delivered to your inbox. You can unsubscribe at any time and we’ll never share your details to third parties.
More information Privacy policy
Daily science news on research developments and the latest scientific innovations
The latest engineering, electronics and technology advances
The most comprehensive sci-tech news coverage on the web
This site uses cookies to assist with navigation, analyse your use of our services, collect data for ads personalisation and provide content from third parties. By using our site, you acknowledge that you have read and understand our Privacy Policy and Terms of Use.

source

Add a Comment

Your email address will not be published. Required fields are marked *